Six dengue vaccine candidates are in various stages of clinical development but developing countries will not receive the benefits if planning does not start now.
The Dengue Vaccine Initiative (DVI) announced today that it has received a 1 million Euro award from the German Federal Ministry of Education and Research (BMBF), the first time it has received such a grant from Germany. The funds will be used to support the development of new dengue vaccines in collaboration with the Instituto Butantan, a biomedical research center in São Paulo, Brazil, and Vabiotech, a vaccine manufacturer in Hanoi, Vietnam.
Held October 24-25 in Bangkok, Thailand, this meeting gathered together representatives from the Ministries of Health (MOH) and National Regulatory Authorities (NRA) of early adopter countries of a dengue vaccine, namely Thailand, Brazil, Colombia, Indonesia, Malaysia, Mexico and the Philippines. There were two parallel sessions: an open session with representatives from MOH, DVI, manufacturers and invited guests, and a closed session between NRAs.
The Consolidated Points for Consideration provides a framework for helping countries interested in being among the first to introduce a dengue vaccine to consider the elements needed for vaccine introduction, and to plan and start preparation in a timely manner.
On May 7th, Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced that they have entered into a definitive agreement for Takeda to acquire Inviragen, whose DENVax dengue vaccine candidate is currently being evaluated in dengue endemic areas.
A new study published in Nature online last week estimates that there are more than three times as many dengue infections as in the official World Health Organization (WHO) figure. The WHO estimates 50-100 million dengue infections a year, while “The global distribution and burden of dengue” report argues that...
On April 9-11, DVI, in collaboration with the Brazil Ministry of Health, convened a meeting in Brasilia, Brazil to bring together several developing countries likely to be among the first-to-introduce dengue vaccines. Major attention wasaccorded to identifying introduction strategies and to regulatory issues.
With the end of 2012 and the start of a new year, we wanted to take this opportunity to review the progress that has been made in heightening public awareness and political will around dengue vaccines, and in progress toward dengue vaccine development, including the first Phase 2 clinical trial results for a dengue vaccine candidate.
The Financial Times reports on dengue and the challenges of developing a dengue vaccine.
The Dengue Vaccine Initiative’s latest newsletter includes an update on dengue vaccines and discusses next steps in the development of a dengue vaccine.